Cargando…
Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration
PURPOSE: To compare the efficacy and safety of 1.25 mg versus 2.5 mg intravitreal bevacizumab (IVB) for treatment of choroidal neovascularization (CNV) associated with agerelated macular degeneration (AMD). METHODS: In this randomized clinical trial, consecutive patients with active CNV associated w...
Autores principales: | Modarreszadeh, Mehdi, Naseripour, Masood, Ghasemi-Falavarjani, Khalil, Nikeghbali, Aminollah, Hashemi, Masih, Parvaresh, Mohammad-Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ophthalmic Research Center
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589230/ https://www.ncbi.nlm.nih.gov/pubmed/23479531 |
Ejemplares similares
-
Intravitreal Bevacizumab for Pseudophakic Cystoid Macular Edema; a Systematic Review
por: Ghasemi Falavarjani, Khalil, et al.
Publicado: (2012) -
Complement Factor H Y402H and LOC387715 A69S Polymorphisms in Association with Age-Related Macular Degeneration in Iran
por: Nazari Khanamiri, Hossein, et al.
Publicado: (2014) -
Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration
por: Salehipour, Masoud, et al.
Publicado: (2010) -
Vitrectomy for Posterior Segment Intraocular Foreign Bodies, Visual and Anatomical Outcomes
por: Falavarjani, Khalil Ghasemi, et al.
Publicado: (2013) -
Pars Plana Vitrectomy and Intravitreal Phacoemulsification for Dropped Nuclei
por: Ghasemi Falavarjani, Khalil, et al.
Publicado: (2012)